Abstract:This document was prepared by the Safety Pharmacology Subcommittee of the Oligonucleotide Safety Working Group (OSWG), a group of industry and regulatory scientists involved in the development and regulation of therapeutic oligonucleotides. The mission of the Subcommittee was to develop scientific recommendations for the industry regarding the appropriate scope and strategies for safety pharmacology evaluations of oligonucleotides (ONs). These recommendations are the consensus opinion of the Subcommittee and do not necessarily reflect the current expectations of regulatory authorities. 1) Safety pharmacology testing, as described in the International Conference on Harmonisation (ICH) S7 guidance, is as applicable to ONs as it is to small molecule drugs and biotherapeutics. 2) Study design considerations for ONs are similar to those for other classes of drugs. In general, as with other therapeutics, studies should evaluate the drug product administered via the clinical route. Species selection should ideally consider relevance of the model with regard to the endpoints of interest, pharmacological responsiveness, and continuity with the nonclinical development program. 3) Evaluation of potential effects in the core battery (cardiovascular, central nervous, and respiratory systems) is recommended. In general: a. In vitro human ether-a-go-go-related gene (hERG) testing does not provide any specific value and is not warranted. b. Emphasis should be placed on in vivo evaluation of cardiovascular function, typically in nonhuman primates (NHPs). c. Due to the low level of concern, neurologic and respiratory function can be assessed concurrently with cardiovascular safety pharmacology evaluation in NHPs, within repeat-dose toxicity studies, or as stand-alone studies. In the latter case, rodents are most commonly used. 4) Other dedicated safety pharmacology studies, beyond the core battery, may have limited value for ONs. Although ONs can accumulate in the kidney and liver, evaluation of functional changes in these organs, as well as gastrointestinal (GI) and unintended "pro-inflammatory" effects, may be best evaluated during repeat-dose toxicity studies. Broad receptor- or ligand-binding profiling has not historically been informative for most ON subclasses, but may have value for investigative purposes.

Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics.

Recommendations for safety pharmacology evaluations of oligonucleotide-based therapeutics.

OSWG Recommended Approaches to the Nonclinical Pharmacokinetic (ADME) Characterization of Therapeutic Oligonucleotides

Considerations for assessment of reproductive and developmental toxicity of oligonucleotide-based therapeutics.

Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides

Assessment of the Immunogenicity Potential for Oligonucleotide-Based Drugs.

OSWG Recommendations for Genotoxicity Testing of Novel Oligonucleotide-Based Therapeutics.

Regulatory considerations for oligonucleotide drugs: updated recommendations for pharmacology and toxicology studies.

Preclinical Safety Assessment of Therapeutic Oligonucleotides

Considerations of the Japanese Research Working Group for the ICH S6 & Related Issues Regarding Nonclinical Safety Assessments of Oligonucleotide Therapeutics: Comparison with Those of Biopharmaceuticals

Meeting report: oligonucleotide ADME workshop

Preclinical safety assessments of mRNA-targeting oligonucleotide therapeutics

Delivery of Oligonucleotides with Lipid Nanoparticles.

Delivery of Oligonucleotide Therapeutics: Chemical Modifications, Lipid Nanoparticles, and Extracellular Vesicles

Delivery of oligonucleotide‐based therapeutics: challenges and opportunities

Oligonucleotide delivery: a patent review (2010 – 2013)

Considerations in the Immunogenicity Assessment Strategy for Oligonucleotide Therapeutics (ONTs)

Lipoplex-based therapeutics for effective oligonucleotide delivery: a compendious review

Perspectives on the Designation of Oligonucleotide Starting Materials

Delivery of Oligonucleotides: Efficiency with Lipid Conjugation and Clinical Outcome

Chemistry, structure and function of approved oligonucleotide therapeutics